51516-96-2

Upstream product

• 99-09-2 3-nitro-aniline 

Downstream Products

• 18265-83-3 acetone-(3-nitro-phenylhydrazone) 
• 110570-12-2 4-Hydroxy-3-{1-[(3-nitro-phenyl)-hydrazono]-ethyl}-chromen-2-one 
• 771-03-9 3-acetyl-4-hydroxy-6-methyl-2H-pyran-2-one 
• 85094-18-4 1-(3-nitrophenyl)-3,4-dimethylpyrano<2,3-c>pyrazole-6(1H)-one 
• 113752-93-5 N-(3-nitro-phenyl)-N'-trityl-hydrazine 
• 166974-77-2 tert-butyl 2-(3-nitrophenyl)hydrazinecarboxylate 
• 134271-93-5 1-(3-nitrophenyl)-2-propylidenehydrazine 
• 476637-05-5 2-(3-nitrophenyl)-5-tert-butyl-2H-pyrazol-3-yl-amine 
• 672305-19-0 Z-6-trimethylsianyl-hexa-3,5-diyn-2-one 3-nitrophenylhydrazone 
• 24760-06-3 (3-nitro-phenyl)-trityl-diazene 
• 85094-53-7 5-Bromo-3,4-dimethyl-1-(3-nitro-phenyl)-1H-pyrano[2,3-c]pyrazol-6-one 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Design, synthesis, crystal structures, and insecticidal activities of eight-membered azabridge neonicotinoid analogues

Three series of novel azabridge neonicotinoid analogues were designed and synthesized, which were constructed by starting material A, glutaraldehyde, and primary amine hydrochlorides (aliphatic amines, phenylhydrazines, and anilines). Most of the eight-membered azabridge compounds presented higher insecticidal activities than oxabridged compound B against cowpea aphid (Aphis craccivora) and brown planthopper (Nilaparvata lugens). Compared with imidacloprid, some azabridged compounds exhibited excellent insecticidal activity against brown planthopper. The crystal structures and bioassay indicated that changing bridge atoms from O to N could lead to entirely different conformations, which might be the important influential factor of the bioactivities.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.